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The Rho family of GTPases belongs to the Ras superfamily of low molecular weight
(∼21 kDa) guanine nucleotide binding proteins. The most extensively studied members
are RhoA, Rac1, and Cdc42. In the last few decades, studies have demonstrated that
Rho family GTPases are important regulatory molecules that link surface receptors to the
organization of the actin and microtubule cytoskeletons. Indeed, Rho GTPases mediate
many diverse critical cellular processes, such as gene transcription, cell–cell adhesion, and
cell cycle progression. However, Rho GTPases also play an essential role in regulating
neuronal morphology. In particular, Rho GTPases regulate dendritic arborization, spine
morphogenesis, growth cone development, and axon guidance. In addition, more recent
efforts have underscored an important function for Rho GTPases in regulating neuronal
survival and death. Interestingly, Rho GTPases can exert either a pro-survival or pro-death
signal in neurons depending upon both the cell type and neurotoxic insult involved. This
review summarizes key ﬁndings delineating the involvement of Rho GTPases and their
effectors in the regulation of neuronal survival and death. Collectively, these results suggest
that dysregulation of Rho family GTPases may potentially underscore the etiology of some
forms of neurodegenerative disease such as amyotrophic lateral sclerosis.
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INTRODUCTION
The Rho GTPase family belongs to the Ras superfamily of low
molecular weight (∼21 kDa) guanine nucleotide binding pro-
teins. Although the Rho GTPase family is further divided into
seven subfamilies (Rho, Rac, Cdc42, Rnd, RhoD, RhoBTB,
and RhoH), the most extensively studied members are RhoA,
Rac1, and Cdc42. Multiple studies have demonstrated that Rho
family GTPases are important regulatory molecules that link sur-
face receptors to the organization of the actin and microtubule
cytoskeletons. In particular, RhoAmediates the formation of stress
ﬁbers and focal adhesions, Rac1 induces lamellipodia formation
and membrane rufﬂes, and Cdc42 elicits formation of ﬁlopo-
dia and microspikes (Hall, 1998). However, the involvement of
Rho GTPases in regulating other essential cellular functions has
also been described, such as gene transcription (Hill et al., 1995),
cell cycle progression (Olson et al., 1995), and cellular survival
and death (Heasman and Ridley, 2008; Linseman and Loucks,
2008).
Similar to Ras family GTPases, activation of Rho GTPases
is regulated by cycling between an inactive GDP-bound state
and an active GTP-bound state (Figure 1). Rho family GTPase
activation is facilitated by guanine nucleotide exchange factors
(GEFs) that promote the exchange of GDP for GTP while inacti-
vation of Rho GTPases is induced by GTPase activating proteins
(GAPs) that stimulate the intrinsic ability of Rho GTPases to
hydrolyze GTP to GDP. The third class of molecules that regu-
late Rho GTPase activity, guanine dissociation inhibitors (GDIs),
sequester Rho GTPases in a GDP-bound state in the cytosol.
The dissociation of GDIs is required for membrane localization
and subsequent activation of Rho family GTPases (Figure 1).
Rho family GTPases contain an ∼200 amino acid residue Dbl
homology (DH) domain and an adjacent, C-terminal, 120
residue pleckstrin homology (PH) domain. The DH domains
of Rho GTPases facilitate interaction with GEFs and the sub-
sequent exchange of GTP for GDP while the PH domains
bind phosphoinositides to localize Rho GTPases to the plasma
membrane (Rossman et al., 2005). More recent studies have elu-
cidated ubiquitin-dependent proteasomal degradation of Rho
family GTPases as a novel mechanism controlling their signaling
output.
In accordance with a conserved function in regulating
cytoskeletal dynamics, Rho GTPases are critical mediators of
neuronal growth cone dynamics, dendritic spine formation,
and axonal pathﬁnding. Indeed, an early study highlighted a
role for Rho family GTPases in regulating neuronal polarity
as cultured hippocampal neurons exposed to either cytocha-
lasin D or Clostridium difﬁcile Toxin B (ToxB; an inhibitor
of Rho, Rac, and Cdc42) demonstrated a complete loss of
F-actin concomitant with the formation of multiple axon-like
protrusions, underscoring a role for Rho GTPases in neuronal
polarization (Bradke and Dotti, 1999). Additional studies have
highlighted that Rac/Cdc42 and Rho typically exhibit an antag-
onistic relationship to determine neuronal morphology. For
instance, an elegant study by Kozma et al. (1997) demonstrated
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FIGURE 1 | Activation of Rho family GTPases. Guanine nucleotide
exchange factors (GEFs) catalyze the conversion of GDP to GTP to enhance
Rho GTPase activation. GTPase activating proteins (GAPs) inactivate Rho
GTPases by stimulating the ability of Rho GTPases to hydrolyze GTP to GDP.
Finally, guanine dissociation inhibitors (GDI) regulate Rho GTPase activation
by sequestering Rho GTPases in a GDP-bound state in the cytosol.
that microinjection of Rac or Cdc42 into N1E-115 neuroblastoma
cells enhanced growth cone development and neurite outgrowth,
whereas the Rho inhibitory cytotoxin Clostridium botulinum
C3 coenzyme abolished Rho-dependent growth cone collapse
and neurite retraction. In addition to growth cone remod-
eling, in the regulation of dendritic spine formation, stim-
ulation of N-methyl-d-aspartate (NMDA) receptors increases
Rac1 and Cdc42 activities while decreasing RhoA activity to
promote dendritic growth and branching (Newey et al., 2005).
Thus, Rho family GTPases are essential regulators of neuronal
morphology.
Given the dynamic nature of the neuronal cytoskeleton, pre-
cise spatial and temporal regulation of Rho family GTPases is
required for proper neuronal morphology. For example, a pre-
vious FRET-based study demonstrated that although PC12 cells
exposed to nerve growth factor show enhanced activation of Rac1
and Cdc42 in extending growth cones, Rac1 activation occurs
primarily in the distal half of growth cones while Cdc42 activ-
ity is localized to the distal microspikes of neuronal growth
cones (Aoki et al., 2004). Nonetheless, although tight regula-
tion of Rho GTPases is often attributed to the spatio-temporal
activation of GEFs and GAPs, more recent data utilizing novel
space- and time-sensitive approaches have begun to unravel com-
plex signaling networks that control the precise activation of
Rho family GTPases in neurons and other cells (reviewed in
Pertz, 2010). These data demonstrate the critical importance of
maintaining precise spatio-temporal regulation of Rho family
GTPases.
Similar to the opposing functions exerted between members
of the Rho GTPase family in the maintenance of neurite out-
growth and growth cone formation, Rac activation typically
promotes neuronal survival while Rho activation often elicits neu-
ronal death (Luo, 2000; Linseman and Loucks, 2008). In the
current review, we focus on the involvement of Rac GTPase
and Rho GTPase in regulating neuronal survival. We ﬁrst dis-
cuss the critical functions of Rho family GTPases in mediating
neuronal survival in vitro. Next, we review the essential role
that Rho GTPases play in proper nervous system development.
Finally, we examine evidence supporting dysregulation of Rho
family GTPases as a causative factor in various neurodegenerative
diseases.
Rac GTPase AND Rho GTPase ACT IN AN ANTAGONISTIC
MANNER TO REGULATION NEURONAL SURVIVAL
The essential functions of Rho family GTPases in regulating
neuronal growth cone formation, neurite outgrowth, and nervous
system development suggest that Rho GTPases have an impor-
tant and conserved function in mediating neuronal survival and
death. Indeed, similar to the opposing functions exerted between
members of the Rho GTPase family in maintenance of neurite
outgrowth and growth cone formation, Rac activation typically
promotes neuronal survival while Rho activation elicits neuronal
death. In further support of an antagonistic relationship between
Rac GTPase and Rho GTPase, recent efforts have identiﬁed a
key signaling network that maintains neuronal survival down-
stream of these Rho family GTPases, discussed in detail below
(Figure 2).
Typically, Rac and its downstream effectors promote neu-
ronal survival, while Rho and its downstream effectors are
capable of inducing neuronal apoptosis. In particular, Rac
GTPase can signal to the downstream effector p21-activated
kinase (PAK) to promote survival of neurons (Johnson and
D’Mello, 2005; Loucks et al., 2006). In neurons and other cells,
PAK is known to promote cellular survival through activation
of mitogen activated protein kinase (MAPK) pathways which
inhibit pro-apoptotic members (e.g., Bad) and enhance the
FIGURE 2 | Rho GTPase signaling pathways regulating neuronal
survival. Rho activates a downstream ROCK/PTEN pathway that indirectly
inactivates the pro-survival protein Akt to suppress neuronal survival. Rho
can also function to provoke apoptosis via activation of either p38- or
JNK-dependent signaling pathways which elicit apoptosis through
activation of pro-apoptotic members of the Bcl-2 family of proteins. In
opposition to Rho, Rac signals through PI3K to activate Akt to enhance
neuronal survival. Rac can also promote neuronal survival via activation of
PAK and enhanced ERK-dependent stimulation of pro-survival members of
the Bcl-2 family of proteins.
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expression of pro-survival members (e.g., Bcl-xL) of the Bcl-2
family of proteins (Zha et al., 1996; Schürmann et al., 2000;
Loucks et al., 2006; Stankiewicz et al., 2012). In addition, Rac
stimulates the key prosurvival phosphatidyl inositol-3 kinase
(PI3K)/Akt pathway that inhibits multiple pro-apoptotic Bcl-2
family proteins (e.g., Bad and Bax) while inducing pro-survival
Bcl-2 expression. These Rac-dependent pathways actively sup-
pressmitochondrial apoptosis but are antagonizedbyRho through
activation of its downstream effector, Rho kinase (ROCK),
which activates the Akt-inhibitory phosphatase tension homolog
(PTEN) phosphatase (Figure 2). The inhibition of Akt by the
Rho/ROCK/PTEN pathway occurs indirectly as PTEN dephos-
phorylates phosphatidylinositol (3, 4, 5)-triphosphate (PIP3)
into phosphatidylinositol (4,5)-biphosphate (PIP2) to terminate
Akt activation (Lai et al., 2014). Maintaining a balance between
these Rac dependent pro-survival signals andRho-dependent pro-
apoptotic signals is essential to the survival of many types of
neurons including cerebellar granule neurons (CGNs) and spinal
motor neurons.
Rac GTPase AND Rho GTPase REGULATE NEURONAL
SURVIVAL AND APOPTOSIS IN VITRO
Early studies utilizing 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) reductase inhibitors (statins) highlighted a likely role
for Rho GTPases in regulating neuronal apoptosis. For exam-
ple, inhibitors of HMG-CoA reductase decrease the localiza-
tion of Rho GTPases to the plasma membrane by suppress-
ing the synthesis of mevalonate, a precursor required for
the isoprenylation of Rho GTPases. Consequently, these com-
pounds induce apoptosis in human brain explants and in
a variety of in vitro neuronal models, including brain neu-
roblasts, PC12 cells, and primary rat cortical, hippocampal,
and CGNs (Kumano et al., 2000; Tanaka et al., 2000; Garcia-
Roman et al., 2001; Meske et al., 2003; März et al., 2007).
More recent studies performed in vitro in diverse neuronal cell
types have clariﬁed that while Rac GTPase typically promotes
neuronal survival, Rho GTPase generally provokes neuronal
apoptosis.
In recent years, an essential pro-survival function for Rac
GTPase has been described inmany diverse in vitro neuronalmod-
els. In particular, we have demonstrated a central pro-survival
function for Rac GTPase in CGNs. We have previously shown
that Clostridium difﬁcile ToxB, a broad-spectrum inhibitor of Rho,
Rac, and Cdc42, induces apoptosis of primary CGNs predom-
inantly through deactivation of Rac1 GTPase (Linseman et al.,
2001; Le et al., 2005; Loucks et al., 2006). Indeed, in healthy CGNs,
Rac GTPase promotes neuronal survival through activation of
a pro-survival MEK1/2/ERK1/2 signaling cascade, acting down-
stream of PAK. This MEK1/2/ERK1/2 signaling cascade functions
to repress c-Jun N-terminal kinase (JNK)/c-Jun-dependent induc-
tion of the pro-apoptotic BH3-only protein Bim. In addition, it
inhibits a pro-apoptotic JAK/STAT5 signaling cascade that sup-
presses transcription of the pro-survival protein Bcl-xL (Linseman
et al., 2001; Le et al., 2005; Loucks et al., 2006; Stankiewicz et al.,
2012). These ﬁnding demonstrate an essential role for Rac1 in
regulating pro-apoptotic members of the BH3-only subfamily of
Bcl-2 proteins.
Cerebellar granule neurons are not the only neuronal
population that shows dependency on Rac function for its sur-
vival. For instance, expression of a dominant-negative mutant
of Rac1 in primary cultures of embryonic rat spinal motor
neurons is sufﬁcient to induce signiﬁcant cell death and cause
suppression of axon outgrowth in the remaining motor neu-
rons (Jacquier et al., 2006). Moreover, in a motor neuronal
cell line, expression of constitutively active Rac1 protects these
cells from the deleterious effects of Cu, Zn-superoxide dismu-
tase (SOD1) mutants (Kanekura et al., 2005). Consistent with
many other studies, this Rac-dependent neuroprotection was
mediated through a P13K/Akt pathways, More recently, cell
death induced in primary cultures of rat cerebral cortical neu-
rons by exposure to methylmercury was shown to involve a
marked downregulation of Rac1 expression (Fujimura et al.,
2009). In a similar manner, primary cultured cortical neurons
were induced to undergo apoptosis by expression of dominant-
negative Rac1, but were protected from glutamate-induced cell
death by expression of constitutively active Rac1 (Johanna et al.,
2010).
In opposition to the pro-survival signaling cascades that are
activated by Rac GTPase in diverse in vitro neuronal models,
activation of Rho GTPase typically elicits neuronal apopto-
sis in response to multiple degenerative insults. For example,
RhoA GTPase activation elicits p38alpha/MAPK-dependent CGN
apoptosis following glutamate-induced excitotoxicity (Semenova
et al., 2007). Interestingly, RhoA-induced apoptosis was sensi-
tive to the pro-survival protein Bcl-2, further highlighting the
ability of Rho family GTPases to transmit signals to down-
stream apoptotic machinery. Similarly, a RhoA-p38alpha MAPK
pro-apoptotic pathway is induced by NMDA in primary cor-
tical and hippocampal neurons (Semenova et al., 2007). In an
in vitro model of Phenylketonuria brain injury, phenylalanine
induced mitochondrial-dependent apoptosis of cortical neurons
via a mechanism consistent with activation of RhoA. Further-
more, brain-derived neurotrophic factor protected cortical neu-
rons from phenylalanine-induced apoptosis by suppressing Rho
activation (Zhang et al., 2010). Finally, corticohippocampal neu-
rons deﬁcient in RhoB are resistant to staurosporine-induced
apoptosis (Barberan et al., 2011). Collectively, these data indi-
cate that aberrant activation of RhoA and/or RhoB may con-
tribute to neuronal apoptosis in a variety of in vitro models of
neurodegeneration.
Thepro-apoptotic effects of Rho inneurons are often attributed
to its downstream effector, ROCK. In NMDA-induced excito-
toxicity in the rat retina, both RhoA and ROCK2 levels are
signiﬁcantly increased prior to neuronal death. Moreover, a
ROCK inhibitor, fasudil, prevents the upregulation of both
RhoA and ROCK2 and reduces cell loss (Kitaoka et al., 2004).
Fasudil also enhances neuronal viability in brain slices or
PC12 cells exposed to oxygen-glucose deprivation (Yamashita
et al., 2007; Li et al., 2009b). Rho/ROCK signaling does not
only act in a pro-death manner downstream of ischemic or
excitotoxic stimuli. In addition, a Rho/ROCK pathway also
mediates the pro-apoptotic effects of phenylalanine in cultured
cerebral cortical neurons (Zhang et al., 2007). Finally, ROCK
inhibitors signiﬁcantly protect cultured cortical neurons from
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toxicity induced by either aluminum or methylmercury exposure
(Chen et al., 2010; Fujimura et al., 2011). Collectively, the
above ﬁndings indicate that Rho/ROCK signaling often acts in
opposition to Rac pro-survival signaling to promote neuronal
apoptosis.
Many studies in neurons support the general model that
Rac/Cdc42 elicit neurite outgrowth and growth cone develop-
ment while Rho induces neurite retraction and growth cone
collapse. However, it is important to note that, in certain cir-
cumstances, Rho family GTPases can have unanticipated effects
on neuronal morphology. For example, expression of a domi-
nant negative mutant of Rac1 has been demonstrated to promote
neurite outgrowth in dorsal root ganglion (DRG) cells (Fournier
et al., 2003) and constitutively active Rac1 increases the pro-
portion of collapsed growth cones in DRG neurons (Jin and
Strittmatter, 1997; Vastrik et al., 1999). Similarly, constitutive acti-
vation of Rac1 was shown to decrease the length of the longest
neurite in mouse cortical neurons (Kubo et al., 2002). Further-
more, in some studies, Rho GTPase has been demonstrated to
induce neurite formation. Indeed, expression of dominant nega-
tiveRhoA inhibited axongrowth in culturedhippocampal neurons
(Ahnert-Hilger et al., 2004). Moreover, it is interesting to note that
exposure of CGNs to low concentrations of the neural chemokine
stromal cell-derived factor-1 (SDF-1) elicited RhoA-dependent
axonal elongation, while CGNs subjected to high concentrations
of SDF-1 demonstrated inhibition of axon formation (Arakawa
et al., 2003). While these apparent discrepancies in Rho fam-
ily GTPase functions may reﬂect differences in either organism
speciﬁc- or cell type-speciﬁc regulation of neuronal morphology,
they also further underscore the importance of tight regulation
of Rho GTPase activation in order for proper nervous system
development.
Rho GTPases IN NERVOUS SYSTEM DEVELOPMENT
In the nervous system, Rho family GTPases play major and
evolutionarily conserved roles in the development, migration,
and plasticity of neurons. Rho, Rac, and Cdc42 have all been
shown to regulate dendritic growth and arborization, as well
as axon guidance (Threadgill et al., 1997; Li et al., 2002; Yuan
et al., 2003). In contrast to the induction of neurite outgrowth,
axonal extension, and dendritic spine morphogenesis typically
elicited by Rac, Rho generally opposes these effects in the cen-
tral nervous system (CNS; Linseman and Loucks, 2008). Here, we
will brieﬂy review the involvement of Rac and Rho in neuronal
development.
Rac IN NEURONAL DEVELOPMENT
The three mammalian Rac isoforms that exist (Rac1, Rac2, and
Rac3) are ∼90% homologous (Didsbury et al., 1989; Haataja et al.,
1997). However, the differential expression patterns of these three
isoforms of Rac indicate that they may have tissue-speciﬁc func-
tions during nervous system development. While Rac1 is ubiqui-
tously expressed, Rac2 is mainly expressed in the hematopoietic
system, and Rac3 is expressed in the brain. Intriguingly, Rac1
is expressed diffusely in the murine brain during development,
while Rac3 expression peaks during times of neuronal matura-
tion and synaptogenesis (Bolis et al., 2003). Rac1-deﬁcient mice
fail to complete gastrulation and are embryonic lethal at E8.5,
demonstrating defects in cell adhesion and migration (Sugihara
et al., 1998). Although Rac2- and Rac3-deﬁcient mice are viable
and fertile, certain strains of these knockouts display signs of
cell type-speciﬁc defects in the hematopoietic system and brain,
respectively (Pedersen and Brakebusch, 2012). Here, we will
focus on the function of Rac1 and Rac3 in regulating neuronal
development.
While loss of function mutations in Drosophila Rac genes result
in defects in axonal growth, guidance, and branching (Hakeda-
Suzuki et al., 2002; Ng et al., 2002), the involvement of Rac in
vertebrate nervous system development is less clear. Given that
genetic inactivation of Rac1 results in embryonic lethality in mice,
more recent studies have focused on the effects of tissue-speciﬁc
deletion of Rac1 on nervous system development, conﬁrming
an important role for Rac1 in neurite outgrowth and axonal
pathﬁnding, as well as neuronal migration. Indeed, conditional
deletion of Rac1 in whole murine brain increased apoptosis and
impaired axonal pathﬁnding and neuronal migration in CGNs
(Tahirovic et al., 2010). Consistent with a critical role for Rac1
in axon guidance during development of the vertebrate CNS,
restricted deletion of Rac1 in the ventral telencephalon of mice
prevents axonal migration across the midline of the corpus cal-
losal and hippocampal commissures but does not affect axonal
outgrowth, indicating that Rac1 primarily controls axon guid-
ance rather than outgrowth in these brain regions (Chen et al.,
2007). Nonetheless, Rac1 regulates mammalian neuronal devel-
opment in a cell type-speciﬁc manner as the Rac-speciﬁc GEF,
Tiam1, has been shown to enhance both neurite outgrowth
and axon formation via its activation of Rac1 (Kunda et al.,
2001).
More recent studies have uncovered an important function for
Rac1 GTPase in neuronal proliferation. For example, deletion
of Rac1 in the neural crest enhanced cell-cycle exit and dimin-
ished both the self-renewal and proliferation of late stage neural
crest-derived stem cells (Fuchs et al., 2009). However, genetic
deletion and virus-based loss of function studies demonstrated
that Rac1 is not required for the proliferation of neural stem
cell/progenitor cells (NS) in the hippocampus during embry-
onic development, but is an important regulator of late dendritic
growth and spine maturation (Vadodaria et al., 2013). Nonethe-
less, the involvement of Rac1 in mediating proliferation in
additional brain regions has also been suggested in recent lit-
erature. For instance, in the murine forebrain, loss of Rac1
reduced proliferation while increasing cell-cycle exit and prema-
ture differentiation of progenitor cells in the subventricular zone
(Leone et al., 2010). Interestingly, a novel function was recently
described for Rac1 in mediating learning-evoked neurogenesis
in the hippocampus of adult mice. While previous reports have
demonstrated that increased production of adult-born neurons
in the hippocampus occurs in a Rac1-independent manner lead-
ing up to learning events, Haditsch et al. (2013) revealed that
neuronal loss of active Rac1 attenuated proliferation and accumu-
lation of neural progenitors during learning events. Future work
will be required to further elucidate the involvement of Rac1 in
mediating neural progenitor proliferation during nervous system
development.
Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 314 | 4
Stankiewicz and Linseman Rho GTPases in neuronal survival
While in vitro and in vivo evidence suggests a crucial function
for Rac1 in nervous system development, to date, relatively few
studies have highlighted a similar function for Rac3. For exam-
ple, genetic disruption of Rac3 in mice did not lead to obvious
developmental defects and histopathological and immunohisto-
chemical analysis did not reveal any abnormalities in the gross
morphology of Rac3−/− brainswhen compared towild typemice.
However, Rac3 knockout mice learned to perform signiﬁcantly
better on a rotarod test than wild type mice, indicating that loss
of Rac3 improves motor learning and retention of coordinated
memory behaviors (Corbetta et al., 2005). Rac3may performover-
lapping functions with Rac1 during nervous system development
as neuronal-speciﬁc knockout of both Rac1 and Rac3 in mice led
to behavioral defects, epilepsy, and premature death at postnatal
day 9. Further analysis of brain tissue in Rac1−/−/Rac3−/− mice
revealed developmental abnormalities in the hippocampus when
compared to wild type brains (Corbetta et al., 2009). Thus, evi-
dence suggests that both Rac1 and Rac3 are important for proper
CNS development.
Rho IN NEURONAL DEVELOPMENT
While three different isoforms of Rho (RhoA, RhoB, RhoC)
have been identiﬁed, the involvement of RhoA in nervous sys-
tem development is best characterized. Nonetheless, RhoB and
RhoC sharemany effectorswithRhoA, suggesting potentially over-
lapping functions. However, while RhoA and RhoC localize to
the cell membrane, RhoB localizes to the membranes of intra-
cellular vesicles. Furthermore, RhoB and RhoC knockout mice
do not display any obvious developmental defects while RhoA
knockout mice are embryonic lethal (Pedersen and Brakebusch,
2012). The involvement of RhoA during development has been
further elucidated through tissue-speciﬁc deletion of RhoA in
the CNS.
Consistent with a role in regulating cytoskeletal dynamics, dele-
tion of RhoA in spinal cord neuroepithelium, midbrain, and
forebrain each led to loss of both adherens junctions and apical-
basal polarity (Herzog et al., 2011; Katayama et al., 2011). Deletion
of RhoA in neuroepithelium resulted in embryonic lethality
and abnormalities in the organization of the ventricular region
(Herzog et al., 2011). While deletion of RhoA in neuroepithelium
resulted in decreased proliferation of neural progenitors, deletion
of RhoA from the midbrain led to increased proliferation of neu-
ral progenitor cells (Katayama et al., 2011). Thus, it is likely that
RhoA exerts cell type-speciﬁc functions during development of
the nervous system.
Using a gene knock-in strategy in which mice express
dominant-negative RhoA in all developing neurons, Sanno et al.
(2010) showed that suppression of Rho activity results in signif-
icant increases in the density and absolute number of neurons
in the somatosensory cortex compared to wild type littermates,
and this effect is due to decreased neuronal apoptosis during early
postnatal development. In neural progenitors, it also appears that
RhoA may mediate survival as expression of a dominant negative
mutant of RhoA enhanced survival and proliferation of NSPCs
(Numano et al., 2009). Thus, recent studies have uncovered RhoA
as an important regulator of neuronal survival and neural stem
cell proliferation.
In a similar manner to Rac1 GTPase, targeted deletion of RhoA
in the cerebral cortex of mice revealed a role for RhoA in regulat-
ing neuronal migration. Mice lacking RhoA in the cerebral cortex
displayed both subcortical band heterotopias and cobblestone
lissencephaly, both of which are attributed to defects in neuronal
migration. While RhoA−/− neurons migrated normally when
transplanted into wild type cerebral cortex, wild type neurons did
not migrate properly when transplanted into RhoA−/− cerebral
cortex. Intriguingly, the defects in neuronal migration were not
due to diminished RhoA activity in neurons, but were attributed
to destabilization of the actin and microtubule cytoskeleton of
the radial glia scaffold, which directs migrating neurons (Cappello
et al., 2012). Therefore, unlike the role of Rac1 in regulating neu-
ronal migration, limited evidence suggests that RhoA may not be
required for migration in neurons but instead directs migration
through its effects on the actin and microtubule cytoskeleton in
radial glia cells.
While the involvement of RhoA in neuronal development has
been a recent subject of investigation, relatively few studies have
examined the role of RhoB in CNS development. Nonetheless,
RhoB−/− mice have been generated and while loss of RhoB
does not result in overt signs of developmental defects, mice
lacking RhoB do display signs of memory impairment as paired-
pulse facilitation, post-tetanic potentiation, and the early phase
of long-term potentiation (LTP) are all reduced in RhoB-null
mice. Consistent with the essential role dendritic spines mor-
phogenesis in LTP, spine number was decreased and dendritic
branching was increased in hippocampal neurons of RhoB−/−
mice (McNair et al., 2010). Thus, recent studies have highlighted
functions for both RhoA and RhoB in proper nervous system
development.
DYSREGULATION OF Rac GTPase AND Rho GTPase IN
NEURODEGENERATIVE DISEASES AND NEURONAL INJURY
The essential functions of Rac GTPase and Rho GTPase in medi-
ating nervous system development and neuronal survival indicate
that dysregulation of theseGTPasesmay play a causative role in the
pathology of some forms of neurodegenerative disease. Indeed,
dysregulation of Rac and/or Rho GTPase has been reported
in a variety of neurodegenerative diseases and neuronal trau-
mas, including amyotrophic lateral sclerosis (ALS), Alzheimer’s
disease (AD), Parkinson’s disease (PD), ischemia/reperfusion,
amongst many others. Here, we will review recent advances
examining dysregulation of these GTPases in various models of
neurodegenerative disease (Table 1).
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis is a devastating neuromuscular dis-
order characterized by loss of motor neurons of the motor cortex,
brain stem, and upper and lower spinal cord. Approximately 10%
of ALS cases appear to be caused by a genetic component, while
the remaining 90% are considered sporadic in nature. In 1993, the
glycine to alanine substitution at position 93 in Cu, Zn- super-
oxide dismutase (SOD1) was one of eleven mutations initially
identiﬁed to be causative in familial ALS. Although the G93A
SOD1 mutation remains the best characterized to date, muta-
tions in additional genes such as Alsin (ALS2), Tar DNA-binding
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Table 1 | Dysregulated Rho family GTPase signaling in neurodegenerative disease.
Protein Neurodegenerative disease
Rac (GTPase) ALS: siRNA knock down or inhibition of Rac induces death of NSC34 cells and primary motor neurons (Kanekura et al., 2005;
Jacquier et al., 2006); activation of Rac in microglia induces death of neighboring motor neurons (Harraz et al., 2008; Apolloni
et al., 2013); G93A mSOD1 decreases Rac activity in SH-SY5Y cells and increases Rac1 activity in microglia (Pesaresi et al., 2011;
Apolloni et al., 2013)
AD: diminished expression in patient brains (Zhao et al., 2006); activates APP transcription (Wang et al., 2009); positive regulation
of Aβ production (Boo et al., 2008; Wang et al., 2009); Aβ activatedTiam1/Rac activation (Mendoza-Naranjo et al., 2007, 2012);
human neuroblastoma cells exposed to Aβ to showed diminished activation of Rac1 (Petratos et al., 2008)
HD: interacts with mutant Htt and knockdown of Rac1 reduces caspase-3/7 activity in striatal cells expressing mutant Htt
(Tourette et al., 2014)
PD: wild type LRRK2 activates Rac1 while mutant LRRK2 does not, overexpression of Rac1 rescues SH-SY5Y cells from mutant
LRRK2 (Chan et al., 2011); inhibition of Rac decreased rotenone-induced ROS production from microglia (Zhou et al., 2012);
inhibition of Rac1 reduced 6-OHDA-induced oxidative damage in dopaminergic cells (Philippens et al., 2013)
SCI: Rac1 mediates myelin fragmentation (Jung et al., 2011); Rac1 improved survival and axonal regeneration in optic nerve crush
(Lorenzetto et al., 2013)
I/R: activity is increased (Johanna et al., 2010) or decreased (Zhang et al., 2009); total Rac1 localizes to degenerating neurites
(Johanna et al., 2010); may increase production of ROS (Raz et al., 2010)
PAK (Rac effector) AD: decreased localization in hippocampal sections but increased intraneural aggregates in patients (Zhao et al., 2006);
translocated from the cytosol to granule intracellular bodies that also stain positive for Rac and Aβ (Ma et al., 2008); increased
activity following Aβ42 exposure in hippocampal neurons (Mendoza-Naranjo et al., 2012)
HD: PAK1 and PAK2 bind to mutant Htt, PAK1 colocalizes with mutant Htt in human brains (Luo et al., 2008)
Alsin (Rac GEF) Juvenile-onset ALS: loss of function mutations (Yamanaka et al., 2003; Hadano et al., 2007)
ARFGEF16 (Rac GEF) Sporadic ALS: hypermethylated and downregulated in patients (Figueroa-Romero et al., 2012)
RNGEF (Rho GEF) ALS: forms cytoplasmic inclusions in sporadic and familial patients (Keller et al., 2012; Droppelmann et al., 2013)
ROCK (Rho effector) ALS: ROCK activity is increased in G93A mSOD1 mice and patients (Hu et al., 2003; Capitanio et al., 2012; Conti et al., 2014);
inhibition of ROCK delays onset and extends survival in the G93A mSOD1 mouse (Takata et al., 2013; Tönges et al., 2014)
AD: Rho/ROCK increased production of toxic Aβ fragments (Zhou et al., 2003)
HD: inhibition of ROCK improves rotarod performance and reduces soluble mutant Htt in R6/2 mouse (Li et al., 2009a)
PD: inhibition of ROCK delays onset and extends survival in mice administrated MPTP (Tönges et al., 2012); ROCK inhibition
prevented microglia from eliminating dopaminergic neurons in MPTP-treated mice (Barcia et al., 2012)
SCI: inhibition or knockout of ROCK is protective (Fournier et al., 2003; Duffy et al., 2009; Wu et al., 2009)
I/R: ROCK increased threefold in ischemic mice (Shin et al., 2008); localizes to actin neuroﬁlaments (Yamashita et al., 2007),
fasudil protects in rodent models (Rikitake et al., 2005; Satoh et al., 2007; Wei et al., 2014)
∝-pix (Rac GEF) HD: promotes mutant Htt aggregation in MG251 cells (Eriguchi et al., 2010)
Kalirin-7 (Rac GEF) AD: Kalirin-7 mRNA and protein levels are decreased in human AD hippocampal samples (Youn et al., 2007)
Rho (GTPase) AD: RhoA is decreased in human AD brains and mice overexpressing Swedish mutant APP, RhoA increased in degenerating
neurites of Swedish Aβ mutant mice (Huesa et al., 2010); human neuroblastoma cells exposed to Aβ show enhanced activation
of RhoA and diminished activation of Rac1 (Petratos et al., 2008)
SCI: inhibition of Rho protects (Boato et al., 2010; Boomkamp et al., 2012)
I/R: Rho is upregulated following stroke in humans (Brabeck et al., 2003) and mice (Trapp et al., 2001; Erdo et al., 2004)
ARHGEF10 (Rho GEF) CMTD: constitutively active in patients with slowed nerve conduction velocities and thin myelination of peripheral nerves
(Verhoeven et al., 2003; Chaya et al., 2011)
protein 43 (TDP43), and fused in sarcoma (FUS) have also been
linked to other familial forms of ALS. Recent evidence suggests
that dysregulation of Rho GTPases may be a factor underlying
both genetic and sporadic ALS.
Recessive mutations in a Rac GEF, alsin, have been reported in
juvenile forms of ALS,primary lateral sclerosis, and infantile-onset
ascending hereditary spastic paralysis (Hadano et al., 2007).
When overexpressed in cultured human cells, alsin mutants are
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rapidly degraded, suggesting disease progression occurs through a
mechanismconsistentwith alsin loss-of-function (Yamanaka et al.,
2003). Although alsin can function as a GEF for both Rab5 and
Rac1, alsin colocalizes with Rac1 in the growth cones of neurons
and regulates Rac1 signaling and neurite outgrowth through its
intrinsic GEF activity, thus suggesting a link between Rac1 disrup-
tion and neurodegenerative disease (Topp et al., 2004; Kanekura
et al., 2005; Tudor et al., 2005). These studies highlight that a loss
of Rac activity may underlie the progression of early onset forms
of ALS.
The critical role of Rac in maintaining neuronal survival is
evidenced by the fact that disruptions in Rac signaling have
been shown to induce apoptosis in a variety of diverse neu-
ronal cell types, including primary motor neurons (Kanekura
et al., 2005; Jacquier et al., 2006; Loucks et al., 2006; Stankiewicz
et al., 2012). In spinal motor neurons isolated from embry-
onic rats, siRNA knockdown of alsin induces neurite retraction
and cell death that is abrogated by expression of constitutively
active Rac1 (Jacquier et al., 2006). Furthermore, alsin antago-
nizes NSC34 motor neuronal death induced by the expression
of ALS-causing SOD1 mutants (mSOD1) via activation of a
pro-survival Rac1/PI3K/Akt signaling cascade (Kanekura et al.,
2005). Intriguingly, accumulating evidence suggests that SOD1
may regulate the activity of Rac1 GTPase. In particular, neu-
ronal apoptosis induced via expression of either G93A or H80R
mSOD1 in SH-SY5Y dopaminergic cells correlated with a decrease
in Rac1 GTPase activity. Indeed, expression of a constitutively
active Rac1 GTPase mutant abrogated mSOD1-induced neuronal
death while expression of dominant negative Rac1 GTPase alone
induced apoptosis (Pesaresi et al., 2011). Future studies should
be aimed at determining whether expression of mutant forms
of SOD1 similarly decrease Rac1 activation in motor neurons in
particular.
In addition to mutations that code for alsin and SOD1,
recent evidence also suggests that ARHGEF16, a GEF for Rac
GTPase, is hypermethylated and downregulated in postmortem
sporadic ALS spinal cord samples when compared to samples
from neurologically normal controls (Figueroa-Romero et al.,
2012). Thus, dysregulation of Rac GTPase may be a common
factor underlying both familial and sporadic forms of ALS.
While accumulating evidence has highlighted a critical func-
tion for Rac GTPase in maintaining neuronal survival, the
involvement of Rac in the etiology of ALS has only been
examined recently and the exact mechanism by which disrup-
tions in Rac activity may induce neuronal apoptosis remains
poorly understood. Therefore, alterations in Rac activity in
motor neurons and mouse models of ALS warrants further
investigation.
In a manner dissimilar to motor neurons, several studies indi-
cate that mutant forms of SOD1 associated with the pathology
of ALS have an opposing function in microglia, ultimately result-
ing in enhanced activation of Rac1 GTPase in a redox-sensitive
manner. For example, Harraz et al. (2008) demonstrated that
wild type SOD1 binds to Rac1 and inhibits its intrinsic GTPase
activity under reducing conditions, ultimately increasing active
Rac1 signaling. In the presence of H2O2, the interaction between
wild type SOD1 and Rac1 GTPase was uncoupled. Intriguingly,
ALS causing mutations in SOD1 prevent the enzyme from redox
uncoupling, resulting in enhanced and persistent activation of
Rac1 GTPase in microglia cells. Inevitably, aberrant Rac1 GTPase
activity leads to increased activation of Nox2, a catalytic subunit
of NADPH oxidase, resulting in an overproduction of dam-
aging ROS. In agreement with Rac1-dependent activation of
NADPH oxidase as a contributing factor underlying motor neu-
ron degeneration in the G93A mSOD1 mouse, inhibition of, or
genetic deletion, of Nox2 slows disease progression and increases
survival in this particular mouse model of familial ALS (Wu
et al., 2006; Marden et al., 2007; Valdmanis et al., 2008). Further-
more, Apolloni et al. (2013) recently identiﬁed extracellular ATP
as a potential mechanism by which Rac1 GTPase activity may
be enhanced in microglia of G93A mSOD1 mice. In primary
microglia cells isolated from G93A mSOD1 mice, stimulation
of the P2X7 receptor by its agonist, 2′-3′-O-(benzoyl–benzoyl)
ATP, enhanced Nox2 activation and the production of ROS in
a Rac1-dependent manner when compared to microglia derived
from non-transgenic animals. Thus, recent experimental evidence
suggests that G93AmSOD1may stimulate Rac1GTPase activation
in a P2X7-dependent manner to enhance the release of toxic ROS
from microglia.
Recent studies also implicate aberrantRhoGTPase activity as an
underlying factor in the pathology of ALS. For example, although
the signiﬁcance remains unknown, the Rho GEF, RGNEF, displays
enhanced cytoplasmic inclusions in spinal motor neurons from
both sporadic and familial ALS patients (Keller et al., 2012; Drop-
pelmann et al., 2013). However, future studies will be required to
identify the importance of RGNEF-positive spinal motor neuron
cytoplasmic inclusions. Nonetheless, in accordance with enhanced
Rho GTPase activity as a causative factor to motor neuronal death
in ALS disease progression, ROCK activity is increased in the
G93A mSOD1 mouse model of ALS, as well as sporadic ALS
patients (Hu et al., 2003; Capitanio et al., 2012; Conti et al., 2014).
Tönges et al. (2014) demonstrated that inhibition of ROCK pre-
served neuromuscular junctions and extended the survival of
G93A mSOD1 mice via a mechanism consistent with reduced
microgliosis and decreased release of pro-inﬂammatory cytokines
and chemokines such as TNFα and IL-6. When examining motor
neuron death in G93A mSOD1 mice, Takata et al. (2013) demon-
strated that administration of fasudil slowed disease progression
and reduced motor neuron loss by a mechanism consistent with
reduced activation of ROCK and PTEN and restored activation
of the pro-survival kinase Akt. While the above studies indicate
that a gain of Rho GTPase activity may underlie the progres-
sion of ALS, new studies will need to be carried out to determine
the precise mechanism by which unopposed activation of Rho
GTPase may contribute to the motor neuronal death observed
in ALS.
ALZHEIMER’S DISEASE
Alzheimer’s disease is the most common form of demen-
tia and is characterized by extensive loss of neurons in the
hippocampus and cerebral cortex. The onset of AD corre-
lates with an aberrant accumulation of extracellular amyloid-β
(Aβ) plaques which are the products of proteolytic cleavage
of the membrane protein amyloid precursor protein (APP).
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Aβ plaques have been demonstrated to be at least partially
responsible for the dysregulation of actin polymerization that
underlies synaptic dysfunction observed during AD progres-
sion (Bloom, 2014). Accumulating evidence suggests that dys-
regulated Rho family GTPase activity may correlate with Aβ
production and thereby contribute to the loss of actin polymer-
ization and dendritic spines, which underlies the pathogenesis
of AD.
Although diminished Rac1 expression is observed in AD brains
obtained from patients early in disease (Zhao et al., 2006), recent
evidence suggests a positive correlation between Rac GTPase
activity and APP expression during later stages of AD disease pro-
gression. For example, in primary hippocampal cells, inhibition
of Rac utilizing NSC23766 or expression of a dominant negative
Rac1 mutant reduced APP mRNA and APP protein expression,
indicating that Rac1 activates APP transcription (Wang et al.,
2009). In addition, Rac1 may also contribute to the formation
of toxic Aβ fragments as inhibition of Rac1 diminished gamma
secretase-dependent cleavage of APP in COS-7 cells (Boo et al.,
2008). Interestingly, while these data highlight that Rac1 may
contribute to APP transcription and the generation of toxic Aβ
fragments, recent reports also suggest that Aβ peptides can in
turn, induce the activation of Rac1. For example, addition of
Aβ42 to hippocampal cultures resulted in upregulation of the Rac-
speciﬁc GEF Tiam1, enhanced activation of Rac1, downstream
activation of the Rac effectors PAK1 and LIMK, and increased
actin polymerization (Mendoza-Naranjo et al., 2007, 2012). Thus,
Rac1 GTPase may function in a positive feedback loop with APP
and/or Aβ fragments to regulate the expression and activities of
one another.
Further evidence suggests that alterations of a Rac1-dependent
signaling cascade links expression of toxic Aβ fragments to dis-
ruption of actin polymerization and dendritic spines. Indeed, it
has previously been reported that expression of the downstream
Rac effector, PAK, is decreased in hippocampal sections, while lev-
els of phosphorylated (active) PAK were elevated in intraneural
aggregates during AD progression (Zhao et al., 2006). In human
AD and Tg2576 mice, phosphorylated (active) PAK translocated
from the cytosol to intracellular granule bodies that also stain pos-
itive for Rac1 and Aβ. In primary hippocampal cells, expression
of Aβ induced a similar redistribution of PAK and resulted in a
reduction in dendrites (Ma et al., 2008). Therefore, dysregulation
of PAK signaling may underlie some synaptic defects observed
in AD.
Although these previous studies indicate that enhanced Rac1
activity may contribute to AD progression, the global reduc-
tion of Rac activity in the brains of human AD patients reveals
that the involvement of Rac GTPase in the progression of AD
is complex. In accordance with reduced Rac GTPase activity, it
was previously reported that the mRNA and protein expression
levels of the Rac GEF, Kalirin-7, are reduced in the hippocam-
pus of human AD brains. Kalirin-7 is known to play a critical
role in dendritic spine maintenance. Intriguingly, Kalirin-7 asso-
ciates with iNOS to downregulate its activity in AtT-20, SH-SY5Y,
C6, and Neuro-2A cells. In the human AD hippocampus, ele-
vated expression of iNOS correlates with diminished association
with Kalirin-7 (Youn et al., 2007). Thus, these data suggest that
reduced Kalirin-7 levels may contribute to the pathogenesis of
AD through enhanced activity of iNOS. Future studies will be
critical in determining whether reduced levels of Kalirin-7 con-
tribute to diminished Rac GTPase activity during early stages of
AD progression.
In addition to Rac GTPase, aberrant Rho GTPase activ-
ity has also been linked to the pathology of AD. Indeed,
RhoA is decreased in human AD brains and in the brains
of transgenic mice overexpressing the Swedish double mutant
of APP. Moreover, while RhoA was decreased in synapses of
AD mice, its expression was increased in degenerating neurites
consistent with the involvement of RhoA in neurite retrac-
tion (Huesa et al., 2010). Addition of Aβ to human neurob-
lastoma cells resulted in reduced neurite length concomitant
with enhanced activation of RhoA and diminished activation of
Rac1 (Petratos et al., 2008). Activation of RhoA has also been
correlated with production of Aβ fragments as activation of
Rho and its downstream effector, ROCK, increased production
of toxic Aβ fragments by gamma secretase-dependent cleavage
of APP (Zhou et al., 2003). Thus, aberrant activation of Rho
GTPase may contribute to AD pathology through enhanced neu-
rite retraction, as well as, increased production of toxic Aβ
fragments.
HUNTINGTON’S DISEASE (HD)
Huntington’s disease (HD) is a progressive and fatal autosomal
dominant disorder characterized by loss of cells in the striatum
and cortex, resulting in involuntary body movements (chorea),
cognitive decline, psychiatric conditions, and eventually death.
HD is caused by a mutation in the Huntingtin gene which results
in expansionof aCAGnucleotide repeat. Mutant huntington (Htt)
forms toxic gain-of-function aggregates that underlie the etiology
of HD. Although relatively few studies have examined the involve-
ment of Rho GTPases in the progression of HD, recent efforts
have linked dysregulated Rho family GTPase signaling to both
the production of toxic ROS and mutant Htt aggregation in the
degenerating CNS.
In a similar manner to other neurodegenerative diseases,
the production of ROS is believed to play a role in the etiol-
ogy of HD. Compared to neurologically normal controls, HD
patients show enhanced NADPH oxidase activity and an increase
in ROS in the cortex and striatum of postmortem brain sam-
ples. In the 140Q/140Q mouse model of HD, NADPH oxidase
activity in cortex and striatum correlated with enhanced pro-
duction of ROS and neurite swellings, and was prevented by
treatment with NOX inhibitors. Similarly, mutant HD mice
bred with NOX2 knockout mice showed enhanced survival con-
comitant with decreased NADPH oxidase activity and lowered
production of ROS (Valencia et al., 2013). Given the important
involvement of Rac1 GTPase in activation of NADPH oxidase
activity, this study indicates that aberrant Rac1 activation may
contribute to production of ROS and thereby the pathology
of HD. In addition to the role of Rac1 in contributing to
the production of ROS through activation of NADPH oxidase,
Rac1 interacts with mutant Htt in a yeast two-hybrid screen
and siRNA-mediated knockdown of Rac1 reduces caspase-3/7
activity in striatal cells expressing mutant Htt (Tourette et al.,
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2014). Thus, enhanced Rac1 activation may contribute to the
pathogenesis of HD through either activation of NADPH oxi-
dase in microglia or direct binding to mutant Htt in susceptible
neuronal populations.
The downstream Rac effector, PAK, has also been implicated
in the pathogenesis of HD. PAK1 binds to Htt in vitro and
in vivo and colocalizes with mutant Htt in human HD brains.
Overexpression of PAK1 enhances the aggregation of mutant Htt
and Htt-induced toxicity of HeLa cells independent of its kinase
activity (Luo et al., 2008). In addition to PAK1, a recent study
utilizing a yeast two-hybrid screen identiﬁed PAK2 as a modu-
lator of Htt-induced toxicity (Tourette et al., 2014). Finally, the
PAK-interacting exchange factor (∝-pix), a GEF for Rac and
Cdc42, promotes mutant Htt aggregation in the MG251 neu-
ronal glioblastoma cell line (Eriguchi et al., 2010). Thus, Rac
and its interacting proteins may underlie the neurotoxicity and
aggregation of mutant Htt in HD.
Intriguingly, recent studies have also highlighted an impor-
tant role for ROCK activation in the etiology of HD. Inhibition
of ROCK utilizing Y-27632 has been demonstrated to have neu-
roprotective effects in vitro and in a Drosophila model of HD.
More recently, Y-27632 has also been shown to improve rotarod
performance and reduce soluble mutant Htt levels in the R6/2
mouse model of HD. However, inhibition of ROCK did not
have a signiﬁcant effect on brain weight, inclusion number or
size, striatal medium spiny neuron number, clasping behavior, or
lifespan (Li et al., 2009a). ROCK may underlie HD progression
through the phosphorylation and inhibition of proﬁlin, which
when overexpressed, reduces the aggregation of polyglutamine-
expanded Htt and androgen receptors in primary neurons (Shao
et al., 2008). These data indicate that enhanced activation of
Rho/ROCK signaling may also contribute to the pathogenesis
of HD.
PARKINSON’S DISEASE
Parkinson’s disease is the most common neurodegenerative move-
ment disorder and is caused by progressive degeneration of
nigrostriatal dopaminergic neurons of the midbrain. Clinically,
PD manifests as a progressive locomotor, cognitive, and behav-
ioral disorder. In the CNS, PD results in the formation of Lewy
bodies containing accumulation of ∝-synuclein. The most com-
mon genetic cause of familial PD is due tomutation in leucine-rich
repeat kinase 2 (LRRK2; Macleod et al., 2006). Although several
geneticmutations have been identiﬁed in PD, exposure to environ-
mental toxins has also been strongly associated with development
of PD.
Expression of disease-causing LRRK2 mutants induces neu-
rite retraction and dopaminergic apoptotic cell death in primary
neurons and in the rodent CNS (Macleod et al., 2006). Interest-
ingly, wild type LRRK2 interacts with and increases the activity
of Rac1 in vitro; however, the disease-causing mutants, G2019S
and R1441C display weakened Rac1 binding while the Y1699C
and I2020T mutations confer increased binding of Rac1. Thus,
the distinct LRRK2 mutations exert differential effects on Rac1
binding. Consistent with diminished Rac1 activity playing a
role in PD pathology, expression of Rac1 rescues SH-SY5Y cells
from neurite retraction and cell death caused by disease-causing
LRRK2 PD mutants (Chan et al., 2011). Therefore, mutations in
LRRK2 may induce neurite retraction and cell death in dopamin-
ergic neurons principally through diminished Rac1 GTPase
activity.
Rotenone is an environmental toxin that induces dopaminer-
gic loss and parkinsonian features when chronically administered
to rodents (Betarbet et al., 2000; Alam and Schmidt, 2002). It has
been previously reported that rotenone induces the production
of ROS not only by inhibition complex I, but also through the
activation of NADPH oxidase (Gao et al., 2002, 2003). In phago-
cytes, rotenone directly interacted with the catalytic subunit of
NADPH oxidase, NOX2, to enhance activation of NADPH oxi-
dase and the formation of ROS. Rac1 enhanced the activation of
rotenone-dependent ROS formation and inhibition of Rac1 utiliz-
ing NSC23766 decreased ROS release from microglia (Zhou et al.,
2012). In a similar manner, inhibition of NADPH oxidase utiliz-
ing apocynin relieved PD symptoms in a marmoset model of the
disease (Philippens et al., 2013). These data indicate that aberrant
activation of Rac inmicrogliamay contribute to enhanced produc-
tion of ROS and underlie the death of neighboring dopaminergic
neurons in PD.
However, the involvement of Rac in mediating neuronal sur-
vival may be much more complex in PD progression as it has
also been demonstrated that hippocampal and dopaminergic
neurons exposed to rotenone showed decreased active Rac1-
GTP and enhanced RhoA-GTP (Sanchez et al., 2008). Thus, in
a manner similar to the antagonistic relationship between Rac
and Rho in regulating the survival of motor neurons, dimin-
ished Rac activity and enhanced Rho activity may contribute to
neuronal death during the progression of some forms of PD,
particularly those forms that are linked to environmental toxin
exposure. Further, Rac1 may contribute to PD disease progres-
sion in a cell type-speciﬁc manner, where loss of Rac GTPase
activity may contribute to the death of neurons while increased
Rac-GTP activity in microglia may contribute to the formation of
toxic ROS.
In addition to rotenone, the neurotoxic 1-Methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) is taken up by dopaminergic
neurons and induces PD symptoms through inhibition of mito-
chondrial complex I of the electron transport chain, leading
to enhanced ROS production and neuronal apoptosis. When
administered to mice, MPTP induces cellular polarization of
microglia and leads to the formation of neuron-glia contacts,
which precede the phagocytosis of dopaminergic cell bodies.
This process may be mediated by ROCK activation as inhi-
bition of ROCK utilizing fasudil prevented microglia motility
and activation of microglia in the substantia nigra of MPTP-
treated mice (Barcia et al., 2012). Indeed, inhibition of ROCK
has shown to enhance survival of dopaminergic neurons and
attenuate axonal loss in the MPTP mouse model of PD (Tönges
et al., 2012). These data indicate that dysregulation of Rho fam-
ily GTPases may underlie both genetic and environmental cases
of PD.
CHARCOT MARIE-TOOTH DISEASE (CMTD)
Charcot marie-tooth disease (CMTD) is an inherited neurolog-
ical disorder that presents as progressive muscle weakness and
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decreased muscle size. The ﬁrst subtype of CMTD is characterized
by demyelination and results in lower nerve conduction veloc-
ities while the second subtype is due to a defect within the
axons themselves. Recent studies have highlighted that dysregu-
lated Rho family GTPase activity may underlie demyelination and
axonal abnormalities. Recently, the T332I mutation was identi-
ﬁed inARHGEF10 in patients exhibiting slowed nerve conduction
velocities and thin myelination of peripheral nerves. ARHGEF10
is a GEF for RhoA that is highly expressed in the peripheral
nervous system and exhibits enhanced activity when harboring
the T332I mutation (Verhoeven et al., 2003; Chaya et al., 2011).
Consistent with activation of RhoA, T332I ARHGEF10 induces
cell contraction through Rho/ROCK signaling in Schwann cells
from rat sciatic nerve. Thus, ARHGEF10 may contribute to the
pathology of CMTD by enhanced activation of RhoA-dependent
cell contraction in the peripheral nervous system (Chaya et al.,
2011).
SPINAL CORD INJURY (SCI)
The spinal cord connects the CNS to the PNS to control sen-
sory and motor functions. Following spinal cord injury (SCI),
this connection can be disrupted to elicit neurological deﬁcits
due to impaired transmission between the CNS and PNS.
The symptoms of SCI vary widely dependent upon the loca-
tion and severity of injury but neurological defects can range
from pain to paralysis. Given the extensive involvement of
Rho GTPases in regulating axonal outgrowth and pathﬁnding,
it is not surprising that members of the Rho GTPase fam-
ily have emerged as key modulators of axonal regeneration
following SCI.
Axonal regeneration following SCI is impeded by increased
expression of the inhibitory myelin-associated proteins, Nogo,
myelin-associated glycoprotein (MAG), and oligodendrocytes-
myelin glycoprotein (OMgp). Early studies inCGNsdemonstrated
that NogoA and MAG mediate their inhibitory effects on neu-
rite outgrowth through disruption of the delicate balance between
antagonistic Rho/ROCK and Rac signaling pathways. In partic-
ular, the inhibitory proteins enhance activation of Rho/ROCK
signaling and diminish activation of Rac1 (Niederöst et al., 2002).
Indeed, in numerous in vivo models of SCI, administration of
either Rho GTPase inhibitors (e.g., C3 transferase) or ROCK
inhibitors (e.g., fasudil, Y-27632) is protective following traumatic
nerve injury (Fournier et al., 2003; Boato et al., 2010; Impellizzeri
et al., 2010; Boomkamp et al., 2012). In vivo, treatment with
fasudil improved motor performance while reducing histologi-
cal damage, the production of proinﬂammatory cytokines, and
activation of caspases following application of vascular clips to
the dura via a laminectomy in mice (Impellizzeri et al., 2010).
In a similar manner, lentiviral injection of dominant negative
ROCK into the adult rat red nucleus protected against dam-
age induced by unilateral rubrospinal tract transection at the
fourth cervical level (Wu et al., 2009). Moreover, ROCKII−/−
mice subjected to dorsal root nerve crush injury recovered
use of the affected forepaw more quickly and demonstrated
enhanced regeneration of sensory axons across the dorsal root
entry zone when compared to controls (Duffy et al., 2009). Col-
lectively, these studies strongly suggest that enhanced Rho/ROCK
signaling impedes axonal growth and regeneration following SCI
injury.
In opposition to Rho, recent studies indicate that activa-
tion of Rac may be a critical feature which promotes axonal
regeneration following SCI. Wallerian degeneration occurs in
response to axonal transection and involves axonal degenera-
tion and fragmentation of the myelin sheath. Jung et al. (2011)
recently determined that a dominant negative Rac1 mutant or
siRNA directed against Rac1 prevents myelin fragmentation in
vivo following sciatic nerve axotomy in mice. However, consti-
tutively active Rac1 failed to induce myelin fragmentation on
uninjured nerves, indicating that Rac1 is an upstream regula-
tor, but is not sufﬁcient to induce myelin degradation following
sciatic nerve injury in mice. In contrast to this prior study indicat-
ing Rac1 has an essential role in myelin fragmentation following
nerve injury, Lorenzetto et al. (2013) demonstrated that injection
of cell-penetrating constitutively active Rac1 mutants following
optic nerve crush improved survival and axonal regenerationwhile
preventing dendrite degeneration. The pro-survival effects of con-
stitutively active Rac1may have beenmediatated through PAK and
ERK1/2 signaling, as both showed enhanced activation in retinal
ganglion cells (Lorenzetto et al., 2013). Therefore, although the
exact mechanism is presently unclear, these studies indicate that
the disrupted balance between Rac and Rho GTPases is a criti-
cal determinant of axonal regeneration following traumatic nerve
injury.
ISCHEMIA/REPERFUSION
Cerebral ischemia and reperfusion (I/R) have devastating effects
on the brain and increasing evidence suggests that neuronal cell
death may be induced by dysregulation of Rho family GTPase
activity. In a similar manner to other neurodegenerative dis-
eases and neuronal traumas, recent data indicate that Rac GTPase
activity may be dysregulated following I/R. For example, active
Rac1 was decreased while total Rac1 redistributed to retract-
ing neuronal processes in the hippocampus 24 h after rats were
exposed to global cerebral ischemia (Johanna et al., 2010). This
study suggests that aberrant activity and localization of Rac1
may contribute to the axonal retraction and neuronal death
following I/R. In other models of I/R, Rac1 has been shown
to be elevated in the hippocampus and may delay neuronal
cell death through of JNK activation (Zhang et al., 2006, 2009).
Alternatively, Rac may also contribute to the release of toxic
ROS from microglia in I/R as administration of NSC23766
to rats 15 min prior to induced cerebral ischemia prevented
an upregulation in ROS and improved hippocampal-dependent
memory and cognitive tests 7–9 days after onset when com-
pared to vehicle-treated rats (Raz et al., 2010). Therefore, although
the consequences of enhanced Rac1 activation are presently
unclear, dysregulated Rac1 activity occurs in several models
of I/R.
In opposition to Rac, Rho is upregulated in the brains of
human stroke patients when compared to controls (Brabeck
et al., 2003). Further, recent in vivo data in rodents has under-
scored the Rho/ROCK pathway as a signiﬁcant determinant of
neuronal cell death following I/R. Following focal ischemia in
mice, expression of Rho is rapidly upregulated in the ischemic
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hemisphere, peaking between 12 and 24 h after onset and may
contribute to neurodegeneration by inducing profound actin
cytoskeletal restructuring (Trapp et al., 2001; Erdo et al., 2004).
Interestingly, the upregulation of Rho precedes cytoskeletal rear-
rangements and DNA damage in neurons (Brabeck et al., 2003).
Rho appears to exert its pro-death function in neurons through
the downstream effector ROCK, as mice exposed to middle
cerebral artery occlusion showed a threefold increased expres-
sion of ROCK in the ischemic penumbra (Shin et al., 2008),
which localized primarily to actin ﬁlaments (Yamashita et al.,
2007).
Recent pre-clinical studies have examined the therapeutic use
of ROCK inhibitors for the treatment of I/R. Administration of
the ROCK inhibitor fasudil signiﬁcantly protected against delayed
neuronal death induced by ischemic injury in gerbils, even when
administered as late as 24 h after the ischemic insult (Satoh et al.,
2007). In a similar manner, fasudil or Y-27632 reduced cerebral
infarct size and improved neurologic outcome in mice after mid-
dle cerebral artery occlusion (Rikitake et al., 2005). Administration
of fasudil following transient cerebral ischemia in rats abrogated
an increase in phosphorylated (active) JNK and caspase-3 (Wei
et al., 2014). Collectively, extensive data indicate that aberrant
activation of the Rho/ROCK pathway underlies neuronal death
in I/R.
CONCLUDING REMARKS
The essential functions of Rho family GTPases in regulating neu-
ronal growth cone dynamics, neurite outgrowth, and neuronal
development suggest that Rho GTPases have an important and
conserved function in mediating neuronal survival and death.
Indeed, although neurodegenerative diseases are complex and
multifaceted, dysregulated activity of Rho family GTPases has
emerged as a common feature underlying the etiology of diverse
degenerative disorders of the central and peripheral nervous sys-
tems. Future research will be aimed at further elucidating the
signaling pathways that are aberrantly activated or disrupted
downstream of Rho GTPases in neurodegenerative diseases. Many
studies suggest that targeting Rho GTPases, or their downstream
effectors, may have beneﬁcial therapeutic effects for the treatment
of neurodegenerative diseases.
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